Jane Street Group LLC Invests $84,000 in Abeona Therapeutics Inc (NASDAQ:ABEO)

Jane Street Group LLC purchased a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 13,216 shares of the biopharmaceutical company’s stock, valued at approximately $84,000.

Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics during the third quarter worth $151,000. Bank of New York Mellon Corp increased its stake in shares of Abeona Therapeutics by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 2,434 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after acquiring an additional 33,831 shares during the period. Simplify Asset Management Inc. bought a new position in Abeona Therapeutics during the 2nd quarter worth approximately $1,732,000. Finally, abrdn plc grew its holdings in Abeona Therapeutics by 158.8% during the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the period. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Trading Down 9.3 %

Shares of Abeona Therapeutics stock opened at $5.09 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a 50-day moving average of $5.95 and a 200-day moving average of $5.68. Abeona Therapeutics Inc has a 52-week low of $3.05 and a 52-week high of $9.01. The stock has a market cap of $221.27 million, a PE ratio of -1.89 and a beta of 1.46.

Analyst Upgrades and Downgrades

ABEO has been the subject of a number of research analyst reports. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.